WallStreetZenWallStreetZen

NASDAQ: HBIO
Harvard Bioscience Inc Stock

$2.46-0.10 (-3.91%)
Updated Oct 3, 2024
HBIO Price
$2.46
Fair Value Price
$1.17
Market Cap
$107.28M
52 Week Low
$2.42
52 Week High
$5.56
P/E
-9.84x
P/B
1.6x
P/S
1.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$101.13M
Earnings
-$10.68M
Gross Margin
58.4%
Operating Margin
-6.18%
Profit Margin
-10.6%
Debt to Equity
0.92
Operating Cash Flow
$9M
Beta
0.86
Next Earnings
Nov 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

HBIO Overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HBIO ($2.46) is overvalued by 110.34% relative to our estimate of its Fair Value price of $1.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HBIO ($2.46) is not significantly undervalued (110.34%) relative to our estimate of its Fair Value price of $1.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HBIO due diligence checks available for Premium users.

Be the first to know about important HBIO news, forecast changes, insider trades & much more!

HBIO News

Valuation

HBIO fair value

Fair Value of HBIO stock based on Discounted Cash Flow (DCF)
Price
$2.46
Fair Value
$1.17
Overvalued by
110.34%
HBIO ($2.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HBIO ($2.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HBIO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.84x
Industry
-61.62x
Market
26.22x

HBIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.6x
Industry
3.96x
HBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HBIO's financial health

Profit margin

Revenue
$23.1M
Net Income
-$2.9M
Profit Margin
-12.7%
HBIO's Earnings (EBIT) of -$6.25M... subscribe to Premium to read more.
Interest Coverage Financials
HBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$128.9M
Liabilities
$61.7M
Debt to equity
0.92
HBIO's short-term assets ($46.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HBIO's short-term assets ($46.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$846.0k
Investing
$458.0k
Financing
$177.0k
HBIO's operating cash flow ($9.22M)... subscribe to Premium to read more.
Debt Coverage Financials

HBIO vs Medical Stocks

TickerMarket Cap1d %P/EP/B
HBIO$107.28M-3.91%-9.84x1.60x
PDEX$103.23M-0.07%50.39x3.34x
KRMD$123.35M+1.51%-10.76x6.59x
AKYA$126.47M-4.66%-2.11x5.68x
MLSS$70.80M-0.76%-13.09x8.90x

Harvard Bioscience Stock FAQ

What is Harvard Bioscience's quote symbol?

(NASDAQ: HBIO) Harvard Bioscience trades on the NASDAQ under the ticker symbol HBIO. Harvard Bioscience stock quotes can also be displayed as NASDAQ: HBIO.

If you're new to stock investing, here's how to buy Harvard Bioscience stock.

What is the 52 week high and low for Harvard Bioscience (NASDAQ: HBIO)?

(NASDAQ: HBIO) Harvard Bioscience's 52-week high was $5.56, and its 52-week low was $2.42. It is currently -55.76% from its 52-week high and 1.65% from its 52-week low.

How much is Harvard Bioscience stock worth today?

(NASDAQ: HBIO) Harvard Bioscience currently has 43,610,883 outstanding shares. With Harvard Bioscience stock trading at $2.46 per share, the total value of Harvard Bioscience stock (market capitalization) is $107.28M.

Harvard Bioscience stock was originally listed at a price of $7.00 in Mar 19, 2001. If you had invested in Harvard Bioscience stock at $7.00, your return over the last 23 years would have been -64.86%, for an annualized return of -4.44% (not including any dividends or dividend reinvestments).

How much is Harvard Bioscience's stock price per share?

(NASDAQ: HBIO) Harvard Bioscience stock price per share is $2.46 today (as of Oct 3, 2024).

What is Harvard Bioscience's Market Cap?

(NASDAQ: HBIO) Harvard Bioscience's market cap is $107.28M, as of Oct 4, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Harvard Bioscience's market cap is calculated by multiplying HBIO's current stock price of $2.46 by HBIO's total outstanding shares of 43,610,883.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.